Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 2Phase NA 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Skin Neoplasms 1Neoplasm Metastasis 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 361Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × gp100 Melanoma Antigen × Clear all
NCT00019682 2017-11-20

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 3 Completed
185 enrolled 11 charts
Dermatologic

Melanoma

NCT00094653 2011-07-11

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Bristol-Myers Squibb

Phase 3 Completed
1,783 enrolled 29 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡